<DOC>
	<DOCNO>NCT01498081</DOCNO>
	<brief_summary>This study COPD patient investigate bronchodilatory effect AZD2115 . AZD2115 test versus placebo active comparators . The safety tolerability AZD2115 include investigation clinically relevant systemically mediate effect also investigate .</brief_summary>
	<brief_title>A Single-dose Study Investigate Effects 3 Different Doses Inhaled AZD2115 COPD Patients</brief_title>
	<detailed_description>A randomised , double-blind , placebo active control , multi-centre , 6 way cross-over , single-dose Phase IIa study investigate local systemic effect 3 different dos inhale AZD2115 patient chronic obstructive pulmonary disease ( COPD )</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Male female nonchildbearing potential ( postmenopausal surgically sterilise ) , age ≥40 year Visit 1 Clinical diagnosis COPD 1 year Visit 1 , accord GOLD guideline Postbronchodilator FEV1 ≥ 40 &lt; 80 % predict normal value postbronchodilator FEV1/FVC &lt; 70 % Reversible airway obstruction Significant disease disorder , opinion Investigator , may either put patient risk participation study , influence result study , patient 's ability participate study . An exacerbation COPD within 6 week prior Visit 1 Treatment systemic glucocorticosteroids 6 week Visit 2 . Recent ongoing respiratory tract infection enrolment period . Need longterm oxygen therapy and/or saturation O2 &lt; 92 % .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>COPD , pulmonary disease</keyword>
</DOC>